Skip to content

Dyne Therapeutics sets IPO terms

September 10, 2020

Dyne Therapeutics (DYN), a developer of therapies for muscle diseases plans an IPO of 10.3M shares, to be priced in a range of $16 to $18.

J.P. Morgan, Jefferies, Piper Sandler and Stifel are underwriting the deal.

Proceeds will be used to finance R&D, develop the FORCE platform and for general corporate purposes.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: